Myc Antibody (6A10): sc-53854

c-Myc Antibody (6A10) is a rat monoclonal IgG2a antibody raised against amino acids 1-262 of human c-Myc. c-Myc rat monoclonal antibody (6A10) recognizes an epitope within the N-terminal region and demonstrates effectiveness in Western blotting, immunofluorescence, and immunoprecipitation applications. Anti-c-Myc monoclonal antibody (6A10) serves as a valuable tool for investigating c-Myc expression, regulation, and activity in various tissues and disease models. The c-Myc protein is a highly conserved transcription factor central to regulating key cellular processes such as proliferation, differentiation, metabolism, and apoptosis. As a member of the Myc family, which includes N-Myc and L-Myc, c-Myc plays a critical role in controlling the expression of genes involved in cell cycle progression, particularly during the G1 to S phase transition, as well as genes regulating cellular growth and metabolism. c-Myc functions through a basic helix-loop-helix leucine zipper (bHLH-Zip) domain, which enables heterodimerization with Max protein, an essential partner that allows c-Myc to bind specific DNA sequences known as E-box motifs (CACGTG). The c-Myc/Max complex acts as a key regulator of transcription, modulating the expression of numerous genes that drive cellular growth and division. In normal cellular function, c-Myc undergoes tight regulation to ensure proper cell cycle control and balanced cell growth. However, dysregulation or overexpression of c-Myc, often through gene amplification or chromosomal translocation, frequently occurs in cancers such as lung, breast, and colon carcinomas, contributing to uncontrolled cell proliferation, resistance to apoptosis, and neoplastic disease development. c-Myc (6A10) antibody recognition of the N-terminal region makes the antibody particularly useful for studying c-Myc′s role in cellular processes and dysregulation in cancer. c-Myc monoclonal antibody (6A10) proves essential for advancing the understanding of c-Myc′s involvement in oncogenic pathways, post-translational modifications, and the development of potential therapeutic interventions for c-Myc-driven cancers.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Myc Antibody (6A10) References:

1. The role of c-myc in cellular growth control.  |  Schmidt, EV. 1999. Oncogene. 18: 2988-96. PMID: 10378694
2. c-Myc regulates transcriptional pause release.  |  Rahl, PB., et al. 2010. Cell. 141: 432-45. PMID: 20434984
3. c-MYC is a radiosensitive locus in human breast cells.  |  Wade, MA., et al. 2015. Oncogene. 34: 4985-94. PMID: 25531321
4. Functional interplay between c-Myc and Max in B lymphocyte differentiation.  |  Pérez-Olivares, M., et al. 2018. EMBO Rep. 19: PMID: 30126925
5. SOX4 is activated by C-MYC in prostate cancer.  |  Dong, H., et al. 2019. Med Oncol. 36: 92. PMID: 31560094
6. Hyperthermia inhibits growth of nasopharyngeal carcinoma through degradation of c-Myc.  |  Li, X., et al. 2022. Int J Hyperthermia. 39: 358-371. PMID: 35184661
7. INSM1 promotes breast carcinogenesis by regulating C-MYC.  |  Guan, Y., et al. 2023. Am J Cancer Res. 13: 3500-3516. PMID: 37693125
8. Development, synthesis and validation of improved c-Myc/Max inhibitors.  |  Yıldırım, S., et al. 2024. J Cell Mol Med. 28: e18272. PMID: 38568057
9. SOX2 represses c-MYC transcription by altering the co-activator landscape of the c-MYC super-enhancer and promoter regions.  |  Ormsbee Golden, BD., et al. 2024. J Biol Chem. 300: 107642. PMID: 39122009
10. The role of c-myc in cell growth.  |  Evan, GI. and Littlewood, TD. 1993. Curr Opin Genet Dev. 3: 44-9. PMID: 8453273

The preferred Myc antibody is Myc Antibody (9E10): sc-40.